Profs. Drs. R I Gregory, Camargo FD and their co-workers from Boston Children’s Hospital, MA, USA; Department of Biological Chemistry and Molecular Pharmacology and Department of Pediatrics, Harvard Medical School, Boston, MA, USA; and Harvard Stem Cell Institute, Boston, MA, USA had reported in the prestigious journal Cell (Feb 27, 2014) that “Hippo Signaling Regulates Microprocessor and Links Cell-Density-Dependent miRNA Biogenesis to Cancer”
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Anti-miRNA-based therapeutics for human cancer: The E2F-1-c-Myc-miRNA-17-92 pathway suppresses widespread miRNA biogenesis via down regulation of its target gene. This data may suggest that miRNA-17-92 cluster functions as an oncomiR by suppressing the network of tumor suppressor miRNAs.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, L, Anti-miRNA-based therapeutics for human cancer: The E2F-1-c-Myc-miRNA-17-92 pathway suppresses widespread miRNA biogenesis via down regulation of its target gene, 16/May/2014, 9.00 am
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
